Latest / Durham News Today | 2 Min News | The Daily News Now!
Eli Lilly’s Earnings Guide Key | Durham News
Eli Lilly’s stock is surging after a spring dip, with analysts eyeing Q2 earnings on August 5th as a pivotal moment. Goldman Sachs maintains a buy rating with a $1,283 price target, forecasting $20B in revenue—aligned with consensus—but factoring in a big R&D charge that will hurt EPS. The real focus? The slower-than-expected launch of the new obesity drug, Foundayo, which has led to lower Q2 sales estimates. Yet Goldman sees this as a minor blip, not a dealbreaker, and is watching for a potential $1B+ guidance raise for the full year—though investors may already be pricing that in…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.